

Additional File

Supplementary Table 1

List of PCR primers and sequence primers in SNP analysis

Gene	Forward Primer	Reverse Primer	Sequence Primer
<i>AlyRef2</i>	GTGTCAGATGCTGACATTCAG	ATTGTCTGCACAGTCCAGTTG	TACGATCGCTCTGGACGAAG
<i>Apcs</i>	GCCAATCTCTGCTACATGAG	GCCAATCTCTGCTACATGAG	GAGCCAAGAGAAAGCGTTTG
<i>Atf6</i>	CAAGTGGGCCTGGATTCTGCAACAG	GCTTACTTCGCGAGTGCAGCATAAG	GAGCGTTGACTTACCAATAG
<i>Casq</i>	ACCATCAGAGTCTGGGGAG	ACAGACAGGAAGCAGGGAG	TGTGTGTGTGGCAGGTCCAG
<i>Cd48</i>	TGGAGGTGGCTGGAGATAG	TACTTCCCCACCTCCCCAG	CCCAGGTCCCCTTCTCTTG
<i>Cd84</i>	TTTCCCATTGGCTCGAGGAG	CTGGAAGTGTGGGAATGAG	CAAGTTCCTTGGCTCCTAG
<i>Fcer1a</i>	ATAAGGACTCTGCTGTGGAG	CTCATCTCCATCTGTTTCAG	GTTAATGGTCATTCATGGATG
<i>Fcer1g</i>	CTGTGTTCTCAGGAGCTGAG	GATACTCCCTGGGTAGGAAG	CCAAGCTCCACCAGCATGTG
<i>Fcgr3</i>	CCTCTCCACGCAAGACTACACAGAG	CCACCACTGCCAGTACAGTCAG	TGATGCTTCCCAGAAACCAG
<i>Fcrg4</i>	AGAGTTTGAGGCCAGCCTGGTCTATAAAG	CTCTTGCTGCCAATCTAACCACCTTAG	TAAAGTCTAGGACAGCCAGGG
<i>Fcrla</i>	GAGCCCTCTCGGTAGAAGATAACCTGAG	GAGGTTTGGTGTCTTCTTCTCTCTCTGAG	ATATTCCCAGGGCAGAAGAG
<i>Fcrlb</i>	CCAACAACAAAACCACAGCAACAGGAG	TCAGTCAGTCACTCCATCCCGAACAG	GGCTCCAATTTGCACACAAG
<i>Ly9</i>	CTAGCCAGTGGGCTTAGAAG	CTTGTGGCTTCCATGGCTAG	GAACAACCGCTCATCTCGAG
<i>Mpz</i>	GGGACATCTTTATGCTGAGACCTTGAGCAG	CTGTTGGTTGAAGCTAATTGCCCTTCTCAG	CTGAGACCTTGAGCAGATAAAG
<i>Nuf2</i>	CTTGGTCTAGGGCAGAGTGTTAATACAG	GTCTCTCATGTCAATTGCTCTGATTGCTCTGTAG	TGTACCTGGGCAGGGATCAG
<i>Rgs4</i>	GGCCTATAAAGCACATGGCAGAAGCAG	GTGGTGTGGGGTTTTCACTAGGGTAAG	CAAATTGGGTCTTACCCTAG
<i>Sh2d1b1</i>	GAGCAAACATGTCTTCTACCTGTGAG TTTGACTTCTCCAGACTTGGTCGTAG	GGCCTTTGCACACGCTAAGCAAG GGACAGGCATGGAGATCACCTGTTAAG	TGTGACCAACCTGAAACTG TCGTAGCAAATCTTTCCTTG
<i>Slamf6</i>	GGTACTGCTCTTCTCAGTAG	ACTGCCTGAACAGTGGCAG	AGCCAGACTGCTGCTGAGAG
<i>Slamf7</i>	GTCTACCTCCCCAGTGCTG	TAGCTCCACCACACACAG	TGCACTTCTTAAGGGAAGAG
<i>Slamf8</i>	CAGCCAGGATCAGGAACAG	CAGCAGAGGGTATAACTGAG	TGTAGGAGGCCTTCCCGGAG
<i>Slamf9</i>	GGTTCTCTGACCTTCTCAGTAG	CTTGCAACTGGTTGTCCGAG	CTGCTTCTGAGACTCCAAAG


Supplementary Table 2

Survival rate of mouse lines

Strain	Survival at 45 wk
B6 Female	17/17
B6. <i>Ipr</i> Female	17/17
<i>RIIB</i> ^{-/-} SENDAI Female	30/30
<i>RIIB</i> ^{-/-} <i>SLAM</i> ¹²⁹ Male	18/18
<i>RIIB</i> ^{-/-} TOKYO Male	4/4
<i>RIIB</i> ^{-/-} TOKYO Female	7/7
<i>RIIB</i> ^{-/-} <i>SLAM</i> ¹²⁹ Female	13/14
<i>RIIB</i> ^{-/-} SENDAI Male	34/35
<i>SLAM</i> ¹²⁹ Female	22/23
<i>SLAM</i> ¹²⁹ Male	26/27
<i>RIIB</i> ^{-/-} TACONIC Female	0/3
<i>RIIB</i> ^{-/-} TACONIC Male	2/3
<i>RIIB</i> ^{-/-} . <i>Ipr</i> Female	0/28
<i>RIIB</i> ^{-/-} . <i>Ipr</i> Male	1/12

Data for *Ipr*-harboring mice are from Yajima K et al. (*Eur J Immunol* 2003, **33**:1020–1029) for comparison.


Supplementary Figure 1



Supplementary Figure 1. Family tree of *Fcgr2b*-deficient (*RIIB*^{-/-}) mice in our laboratory.

The original *RIIB*^{-/-} mice constructed with a 129/B6 hybrid background [13] were backcrossed into the B6 genetic background for 12 generations (N12) as described [16]. At the 18th generation (N18), we obtained *RIIB*^{+/+}*SLAM*¹²⁹ heterozygotes, which were intercrossed to obtain the *RIIB*^{+/+}*SLAM*¹²⁹ line. At the 22nd (N22) generation, *RIIB*^{-/-}*SLAM*^{B6} heterozygotes obtained were intercrossed to generate the N22 *RIIB*^{-/-} line. Further backcrossing of N22 offspring into B6 yielded heterozygotes for *RIIB*^{-/-}*SLAM*¹²⁹ and *RIIB*^{-/-} at the 28th generation (N28), each of which was intercrossed to generate homozygotes of N28 *RIIB*^{-/-}*SLAM*¹²⁹ and N28 *RIIB*^{-/-}*SLAM*^{B6} (*RIIB*^{-/-}). Our *RIIB*^{-/-} mouse line is designated as *RIIB*^{-/-}SENDAI where it is necessary to distinguish it from those obtained from others. We analyzed the following SSLP markers on chromosome 1: *D1Mit100*, *D1Mit102*, *D1Mit501*, *D1Mit34*, *D1Mit268*, *D1Mit105*, *D1Mit15*, *D1Mit36*, *D1Mit205*, *D1Mit270*, *D1Mit147*, *D1Mit146*, *D1Mit113*, *D1Mit355.2*, *D1Mit150*, *D1Mit221*, and *D1Mit17*.

Supplementary Figure 2



Supplementary Figure 2. Estimation of the severity of glomerulonephritis.

The severity of glomerulonephritis was estimated as follows; grade 0, normal; grade 1, neutrophil infiltration and segmental mesangial proliferation; grade 2, limited lobulated glomeruli in grade 1; and grade 3, crescent formation and severe lobulated glomeruli with lymphocyte infiltration. Representative picture for each score is shown with the source of mouse line.